Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurex Corporation -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (371)	11/14/1997 6:45:00 PM
From: John McCarthy	Read Replies (1) \| Respond to of 449

Chinmoy Roy and NeuroInvestment Me confused .... They have $68.0 mil. in the bank now. They suck $10.0 mil. a qtr. in cash. They are 2 Qtrs from a go / nogo on the pain killer thing If go, 1 additional Qtr to get label and get it out the door .. At that point, they would still have $38.0 mil. in the bank. What does Corlopam buy the patient that its equivalents don't. And is it worth and extra $185 a pop? I thought they would have went for market share .... i.e. same or lower PRICE POINT? Hold it ... are we talking REALLY LOUSY MANUFACTURYING COSTS HERE? And the Higher Price needed to get back to a "normal" gross margin %. All things being equal, the gross margin % on Corlopam must be off this planet at that price. We'll find out in a quarter or to. Regards, John McCarthy Regards, John McCarthy